Current issues in the treatment of visceral leishmaniasis

Medical Microbiology and Immunology

Volumn 190, Issue 1-2, 2001, Pages 81-84

  Bryceson, Anthony ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; ANTIRETROVIRUS AGENT; ITRACONAZOLE; KETOCONAZOLE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PYRROLE DERIVATIVE; SITAMAQUINE; STIBOGLUCONATE SODIUM;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DEVELOPING COUNTRY; DISEASE COURSE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; KIDNEY TRANSPLANTATION; LEISHMANIA; MEDICAL ASSESSMENT; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RISK FACTOR; VISCERAL LEISHMANIASIS;

EID: 0035161541     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004300100086     Document Type: Article

References (24)

1. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: Course and impact from 1984 to 1994
2. Epidemia de leishmaniose visceral no estado do Piaui, Brasil, 1980-1986
3. Leishmania and human immunodeficiency virus coinfection: The first 10 years
4. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries
5. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B
6. Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years
7. Comparison of two dosage schedules of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya
8. Leishmaniasis
9. Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis
10. Randomised controlled trial of aminosidine (paromomycin) vs sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India
11. Epidemic visceral leishmaniasis in Sudan: A randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone
12. Rapid accurate field diagnosis of Indian visceral leishmaniasis
13. Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies
14. Short-course of oral miltefosine for treatment of visceral leishmaniasis
15. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of the indian epidemic
16. Visceral leishmaniasis unresponsive to antimonial drugs. II. Response to high dosage sodium stibogluconate or prolonged treatment with pentamidine
17. Immunosuppression in Kenyan visceral leishmaniasis
18. Visceral leishmaniasis and HIV-1 co-infection in southern France
19. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain
20. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis
21. Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in a renal transplant recipient after the occurrence of pancreatitis due to stibogluconate
22. Use of an Itraconazole/allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS
23. Fluconazole plus allopurinol in treatment of visceral leishmaniasis
24. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis